In the United Kingdom, the National Institute of Clinical Excellence (NICE) recommends the use of CGM for people with T2D on multiple daily insulin injections if they have recurrent hypoglycaemia or severe hypoglycaemia, impaired hypoglycaemia awareness, a condition or disability, which means they cannot self monitor their blood glucose by capillary glucose monitoring, would otherwise be advised to self‐measure at least eight times a day, or if they would need help from a care worker or healthcare professional to monitor their blood glucose.2 The gene discussed is INS; the disease is type 2 diabetes mellitus.